Tangent90 announces strategic collaboration with NEJM Group

Enabling greater access to clinical content with secure and compliant delivery to Healthcare Professionals

London, United Kingdom – 8th September 2022: Tangent90 Ltd, a leading provider of digital solutions to help pharmaceutical companies improve their engagement with healthcare professionals (HCPs), has entered into a strategic collaboration with NEJM Group publications (New England Journal of Medicine, NEJM Evidence, NEJM Catalyst, NEJM Journal Watch).

The New England Journal of Medicine (NEJM) is recognised as the world’s leading medical journal. With its long history of publishing trusted, impactful, peer-reviewed original content, NEJM will use Tangent90’s Trustrack links to support digital rights management and seamless access to content for its pharmaceutical clients looking to reach HCPs.  Trustrack links deliver an optimized HCP experience across all channels and provide insights into content utilization, which helps support the identification of ‘next best action’ with ‘next best scientific content’ to deliver the most appropriate content to the HCP.

In recognition of HCP learning preferences and time constraints, NEJM has expanded its Original Research articles by offering both textual summaries (Research Summaries) and video summaries (QuickTake Videos).  These formats support the busy, practising clinician and map particularly well in digital engagement efforts. By working with Tangent90 to make these formats available to its clients via Trustrack, NEJM is expanding opportunities to engage physicians with its high-quality content.

“Providing the best possible access to our content is a strategic objective and delivering a better way to provide physicians access to unbiased, trusted research, supports that objective”, explains Matthew Cann, Managing Director, Research and Publishing, NEJM Group.

Additionally, Tangent90 collaborated with NEJM to extend the Tangent90 Resource Centre platform to include NEJM Group content, tagged in a manner that will expose all appropriate content, beyond the traditional Original Research article.

“We are excited to be supporting NEJM in their innovative and leading approach to digital content provision”, explained Jan van den Burg, CEO at Tangent90. “Our solutions facilitate the use of published scientific content in HCP communication, delivering on the individually expressed HCP needs, recognising the time-pressured environment HCPs work in”, he added.

“Tangent90 has many years of experience in the industry. Our solutions can be used in pharma and third-party channels. For example, our technology partnership with Veeva enables ePrint content use in approved Email, face-to-face and remote meeting content, as well as owned and third-party web channels”, he added. “Our collaboration with NEJM Group will serve up more relevant scientific content in HCP communications, enabling pharma to better serve the HCP community, which ultimately results in better patient outcomes”, he concluded.

Related news

First party data

The first-party data opportunity

The pharma industry has embraced the digital revolution and with that the opportunity to use more readily available data. However, effective digital engagement only works if first-party data (information a company collects directly from its customers and owns) is collected and subsequently used properly.

HCP access

Taking advantage of the HCP access rebound

The latest Veeva Pulse Field Trends Report is out and it discusses the change in access to HCPs. Even pre-pandemic, face-to-face meetings were in decline but the report highlights that this has bounced back, and some. The figure now sits at 60% across all specialities but what is clear is that how interaction takes place has changed.

Marketing insight

Harnessing data-driven HCP engagement

Whether it’s via email, from a congress booth, or a website, we share content with our target audience constantly. For pharma, this content can be the difference between an HCP prescribing their drug or not. It is, therefore, important to understand what happens to that content after the initial interaction with the HCP.

Scroll to Top

Book A Demo

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.